The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
基本信息
- 批准号:10631854
- 负责人:
- 金额:$ 3.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2025-04-08
- 项目状态:未结题
- 来源:
- 关键词:AffinityAntigen PresentationAntigen-Presenting CellsAntigensApoptosisAutoantigensAutoimmuneAutoimmune DiseasesAutoimmune ProcessAutoimmunityB-LymphocytesCD4 Positive T LymphocytesCX3CL1 geneCellsClonal DeletionClone CellsCoculture TechniquesComplexDataDendritesDendritic CellsDevelopmentEducationFOXP3 geneFamilyFractalkineGene RearrangementGenetic TranscriptionGoalsHumanImmuneIn SituIn VitroInsulinKnowledgeLigandsLocationLymphocyteMacrophageMediatingMolecularMononuclearMusNatureOrganOutcomePathologyPeptide/MHC ComplexPeptidesPeripheralPhagocytesPopulationProcessProliferatingReactionRegulatory T-LymphocyteReportingRoleShapesSignal TransductionSiteStructureStructure of thymic cortexStructure of thymic medullaT-Cell DevelopmentT-Cell ReceptorT-LymphocyteThymic epithelial cellThymocyte DevelopmentThymocyte SelectionThymus GlandTissuesWorkanergyautoreactive T cellautoreactivitycell motilitycell typecentral tolerancechemokine receptormicrobiomemigrationmonocytemouse modelneglectpreventprimary lymphoid organresponsespatiotemporalthymocytetooltranscription factor
项目摘要
PROJECT SUMMARY/ ABSTRACT
Autoimmunity is defined as the loss of tolerance to self-antigen resulting in the targeted destruction of tissue by
immune cells. Autoimmune conditions are on the rise globally while our knowledge on how autoimmunity
emerges is still limited. The thymus is a highly structured organ that is essential for T cell development and
education. The nature of the gene rearrangements on the T cell receptor (TCR) allows for recognition of self and
non-self-antigens. Positive selection occurs in the thymus cortex where thymocytes receive survival signals when
selected against self-antigen by cortical thymic epithelial cells (cTECs). Negative selection occurs in the thymus
medulla driven by medullary thymic epithelial cells (mTECs), and a diverse repertoire of antigen presenting cells
(APCs) including different subsets of dendritic cells (DCs) and B cells. The signaling strength of the tri-molecular
complex (TCR-peptide-MHC) between APCs and thymocytes dictates cell fate. Thymocytes who react too
strongly to self-antigens are deleted, become anergic or divert to regulatory T cell (Treg) lineage. In optimal
conditions T cell selection prevents the release of autoreactive T cell clones to the periphery a critical process to
prevent the onset of autoimmunity. However, the mechanisms behind the escape of autoreactive T cells to
the periphery in autoimmune conditions are poorly understood, and the study of T cell education in a
primary lymphoid organ is not feasible in humans. Mouse models have demonstrated to be powerful tools
in thymus studies, as several developmental and functional mechanisms are evolutionary conserved. Migratory
and resident APCs are known to drive clonal deletion and Treg lineage in both the humans and mice. CX3CR1
is expressed in a subset of tolerogenic B cells and Mononuclear phagocytes (MNPs): DCs, macrophages and
monocytes. CX3CR1+ APCs present antigen to CD4+ T cells in peripheral organs. CX3CR1+ APCs in the gut
induce differentiation of peripheral Tregs via transcription factor Foxp3. The close interaction of CX3CR1+ APCs
with CD4+ T cells in the periphery lead us to hypothesize whether a similar population of CX3CR1+ APCs resides
in the thymus to drive selection of T cells and may play a role in thymic Treg development. Our preliminary data
shows a population of CX3CR1+ APCs in the thymus capable of antigen specific stimulation of CD4+ T cells in
vitro. The long-term goal of the proposed work is to understand how autoreactive T cells develop and
escape selection mechanisms in the thymus driven by CX3CR1+ APCs and ultimately drive the
emergence of autoimmune disease. Our studies aim to investigate the contribution of APCs to central T cell
tolerance with the goal of finding potential new targets for treatment of autoimmune disease.
项目总结/摘要
自身免疫被定义为对自身抗原的耐受性丧失,导致组织的靶向破坏,
免疫细胞。自身免疫性疾病在全球范围内呈上升趋势,而我们对自身免疫性疾病
出现仍然有限。胸腺是一个高度结构化的器官,对T细胞发育至关重要,
教育T细胞受体(TCR)上的基因重排的性质允许识别自身,
非自身抗原。阳性选择发生在胸腺皮质,胸腺细胞在此接受存活信号,
通过皮质胸腺上皮细胞(cTEC)针对自身抗原选择。负选择发生在胸腺
由胸腺髓质上皮细胞(mTECs)驱动的髓质,以及多种抗原呈递细胞
在一个实施方案中,所述抗原呈递细胞(APC)包括树突细胞(DC)和B细胞的不同子集。三分子的信号强度
APC和胸腺细胞之间的TCR-肽-MHC复合物决定细胞命运。胸腺细胞也有反应
对自身抗原反应强烈的T细胞被删除,变得无反应性或转向调节性T细胞(Treg)谱系。处于最佳
条件T细胞选择阻止自身反应性T细胞克隆释放到外周,这是一个关键过程,
防止自身免疫的发生然而,自身反应性T细胞逃逸到
自身免疫性疾病中的外周血细胞还知之甚少,
初级淋巴器官在人类中不可行。小鼠模型已被证明是强大的工具
在胸腺研究中,由于一些发育和功能机制在进化上是保守的。洄游
并且已知常驻APC在人和小鼠中驱动克隆缺失和Treg谱系。CX3CR1
在致耐受性B细胞和单核细胞吞噬细胞(MNP)的亚群中表达:DC、巨噬细胞和
单核细胞CX 3CR 1 + APC将抗原呈递给外周器官中的CD 4 + T细胞。肠道中的CX 3CR 1 + APC
通过转录因子Foxp 3诱导外周血T细胞分化CX 3CR 1 + APC的密切相互作用
与外周血中的CD 4 + T细胞相关,这使我们假设是否存在类似的CX 3CR 1 + APC群体,
在胸腺中,它可以驱动T细胞的选择,并可能在胸腺Treg发育中发挥作用。我们的初步数据
显示了胸腺中能够抗原特异性刺激CD 4 + T细胞的CX 3CR 1 + APC群,
体外这项工作的长期目标是了解自身反应性T细胞是如何发育的,
胸腺中由CX 3CR 1 + APC驱动的逃避选择机制,并最终驱动免疫应答。
自身免疫性疾病的出现。我们的研究旨在探讨APC对中枢T细胞的作用,
目的是寻找治疗自身免疫性疾病的潜在新靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHANIE OROZCO Figueroa其他文献
STEPHANIE OROZCO Figueroa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 3.56万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 3.56万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 3.56万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 3.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 3.56万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 3.56万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 3.56万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 3.56万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 3.56万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 3.56万 - 项目类别: